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a  b  s  t  r  a  c  t
Objective: Deferral of blood donors due to low hematocrit and iron depletion is commonly
reported in blood banks worldwide. This study evaluated the risk factors for low hematocrit
and iron depletion among prospective blood donors in a large Brazilian blood center.
Method: A case–control study of 400 deferred donors due to low hematocrit and 456 eligible
whole blood donors was conducted between 2009 and 2011. Participants were interviewed
about selected risk factors for anemia, and additional laboratory tests, including serum
ferritin, were performed. Bivariate and multivariate analyses were performed to assess the
association between predictors and deferral due to low hematocrit in the studied population
and  iron depletion in women.
Results: Donors taking aspirins or iron supplementation, those who reported stom-
achache, black tarry stools or hematochezia, and women having more than one menstrual
period/month were more likely to be deferred. Risk factors for iron depletion were repeat
donation and being deferred at the hematocrit screening. Smoking and lack of menstruation
were  protective against iron depletion.
Conclusion: This study found some unusual risk factors related to gastrointestinal losses that
were associated with deferral of donors due to low hematocrit. Knowledge of the risk factors
can help blood banks design algorithms to improve donor notiﬁcation and referral.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Avenida Dr. Enéas de Carvalho Aguiar, 155, 1
E-mail address: cesarnt@uol.com.br (C. de Almeida-Neto).
http://dx.doi.org/10.1016/j.bjhh.2015.05.008
1516-8484/© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia
reserved.◦ andar, 054003-000 São Paulo, SP, Brazil.





















































trev bras hematol hemot
ntroduction
he high prevalence of anemia is still a public health problem
cross the world in both rich and poor countries.1 Glob-
lly, anemia affects 1.62 billion people, which corresponds to
lmost 25% of the population. Iron deﬁciency is the leading
ause of anemia, but it is seldom present in isolation. Low iron
ntake, poor iron absorption, blood loss as a result of men-
truation, parasitic infections and high iron demand during
regnancy and growth are recognized as the main reasons
or iron deﬁciency. Anemia with iron deﬁciency is an indica-
or of potentially serious negative public health outcomes for
ultiple pathways, including iron deﬁciency of the brain and
uscle.2
Blood donation has also been acknowledged as a cause
f iron deﬁciency and anemia. Blood banks always count
n repeat donors as a safe source to replenish their stocks.
epeat donors have already experienced the process of
onation, have negative test results and are less suscep-
ible to adverse donation reactions. To collect blood from
epeat donors is also less expensive and more  effective than
ecruiting new donors.3 However, iron depletion (ID) as a con-
equence of repeat donations has been known for more  than
0 years and is an important adverse event among regular
onors.4
Worldwide, approximately 10% of blood donation can-
idates are deferred due to low hematocrit (Hct).5–7 In
razilian blood centers, 100,000 units are not collected annu-
lly because candidates present low Hct.8 Consequently, the
lood supply is directly affected. The total number of defer-
als would even be greater if, in addition to Hct, iron stores
ere also measured, as iron deﬁciency appears before low
ct. Finch et al.9 found that on average men  can donate
hree times a year and women can donate half of this
mount before becoming iron depleted. Generally, to defer
 donor is costly and time-consuming. Additionally, donors
ho  are deferred have a lower rate of return for further
onations.10
Although blood centers must maintain a safe and ade-
uate blood supply to attend the demand of patients who need
lood, they must also be concerned about the health of their
onors. An understanding of the risk factors associated with
onor deferral for low Hct and ID can help to improve recruit-
ent of donors, optimize blood collection and increase the
ffer of products to save lives without damaging other lives.
oreover, blood donors identiﬁed with anemia or ID can be
eferred for treatment. The aim of this study was to evaluate
isk factors related to low Hct and ID among prospective blood
onors in a large Brazilian blood center.
ethods
 case–control study was conducted to evaluate the risk fac-
ors related to low Hct levels and ID among 400 individuals
eferred for low Hct and 456 eligible blood donation candi-
ates of the Fundac¸ão Pró-Sangue (FPS), Hemocentro de São
aulo from 2009 to 2011. FPS in São Paulo, Brazil, is located in
he largest public hospital in the city (Hospital das Clínicas). 1 5;3  7(5):306–315 307
Annually, FPS collects approximately 120,000 units of blood
and provides blood components to more  than one hundred
hospitals in the metropolitan region of the city. This study was
approved by the Ethics Committee of Hospital das Clínicas (#
0115.0.015.000-09).
For each donor deferred due to low Hct, another eligi-
ble donor of the same gender, age and donation status was
selected. Donors were selected during the different collection
periods, from Monday to Friday. Selected donors and candi-
dates who accepted to participate in the study and signed a
consent form were interviewed and had an extra blood sample
collected for additional laboratory tests.
The Hct cut-off point adopted to qualify candidates for
blood donation is 38% for females and 39% for males according
to the Brazilian standards issued by the Ministry of Health.
Interviews were conducted by trained physicians and assis-
tant nurses in a private room at the blood center. The following
items were asked during the interview:




(5) Status of the donor i.e., ﬁrst-time donor (never donated
or donated whole blood once more  than ﬁve years pre-
viously), repeat donor (donors who donated whole blood
at least twice in the previous 13 months), and sporadic
donors (donors who donated whole blood at least twice
in an interval greater than 13 months and less than ﬁve
years)
(6) Number of whole blood donations (lifetime and last 13
months)
(7) Type of diet, general, ovo-lacto-vegetarian or vegan
(8) Vitamin supplement intake without iron
(9) Intake of supplements with iron
(10) Iron pill intake
(11) Aspirin intake (afﬁrmative answers were considered if
the participant had taken at least one pill/week over the
previous 12 months)
(12) Frequency (once a month, more  than once a month, in
intervals of 40 days), duration (1 to 3 days, more  than 3
and less than 1 week, more  than one week) and inten-
sity (light, moderate or heavy as indicated by the number
of sanitary pads used) of menstrual ﬂow in the last 12
months for women
(13) Number of pregnancies, including miscarriages, live and
still born
(14) History of smoking and number of cigarettes smoked per
day
(15) History of gastrointestinal (GI) signs and symptoms (life-
time) of stomachache and heartburn, black tarry stools
and hematochezia and
(16) If the participant had ever had an endoscopy.
Additional laboratory tests were performed for each partic-
ipant. This included the following tests: hemoglobin level (Hb
– g/dL), Hct (%), mean corpuscular volume (MCV), mean cor-
puscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), serum iron (g/L), transferrin satura-
tion (%), transferrin (g/L), total iron binding capacity (TIBC)
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Table 1 – Age, gender, race/ethnicity, educational level and donor type of 856 participants.
Variable DA (n = 400) DD (n = 456) Total (n = 856) p-Value
n % n % n %
Donor type
First-time 80 20.0 95 20.8 175 20.4 0.048
Sporadic 51 12.8 31 6.8 82 9.6
Repeat 254 63.5 241 52.9 495 57.8
Missing 15 3.8 89 19.5 104 12.1
Age
18–24 88 22.0 108 23.7 196 22.9 0.549
25–34 133 33.3 132 28.9 265 31.0
35–44 95 23.8 124 27.2 219 25.6
45–54 57 14.3 62 13.6 119 13.9
55–65 20 5.0 28 6.1 48 5.6
Missing 7 1.8 2 0.4 9 1.1
Gender
Male 25 6.3 41 9.0 66 7.7 0.17
Race/ethnicity
Asian 9 2.3 7 1.5 16 1.9 0.243
White 228 57.0 236 51.8 464 54.2
Indian 2 0.5 4 0.9 6 0.7
Black 45 11.3 71 15.6 116 13.6
Mixed 111 27.8 138 30.3 249 29.1
Missing 5 1.3 0 0.0 5 0.6
Educational level
1–8 years 55 13.8 84 18.4 139 16.2 0.052
8–11 years 190 47.5 183 40.1 373 43.6
>12 years 155 38.8 189 41.4 344 40.2
DA: donor accepted; DD: donor deferred.and ferritin level (g/L) in venous samples collected after
the interview. Laboratory analysis was performed according
to standard methods. An automatic analyzer (Coulter Gen S,
Beckman Coulter, Inc., Fullerton, CA, USA) was used for Hb,
Hct, MCV,  MCH  and MCHC measurements. Serum iron, TIBC,
and transferrin saturation were determined ‘in house’ using a
bathophenanthroline (ferrozine) assay. Serum ferritin was bio-
chemically determined using an automatic analyzer Architect
(Architect Clinical Chemistry Analyzers, Abbot Diagnostics,
Abbot Park, IL, USA).
ID was deﬁned as a ferritin value of less than or equal to
30 g/L11,12 or transferrin saturation of less than 20%.13
Data were analyzed as a matched case–control study,
assessing demographics and risk factors associated to defer-
ral for low Hct and ID. Bivariate correlations with deferral due
to low Hct among the entire studied population were ﬁrst
examined. Additionally, bivariate correlations with ID were
assessed only among women. A p-value <0.05 was consid-
ered signiﬁcant. All variables were included in the multivariate
analyses. The odds ratios (OR) of associations between demo-
graphics and risk factors for Hct deferral or ID were calculated
by logistic regression models. The means and standard devi-
ation (SD) of age, Hb, Hct, serum iron, transferrin saturation,
ferritin were calculated for all eligible and deferred donors.
Data were analyzed using the R 3.1.0 statistics program (R Core
Team, 2014).Results
Eight hundred and ﬁfty-six prospective blood donors were
interviewed between July 2009 and July 2011. Of this total,
400 (46.7%) were deferred for low Hct at screening, and 456
(53.3%) were eligible for whole blood donation; 92.3% were
women, 54.2% were white, 31% were between 25 and 35 years
old, 43.6% had 8 to 11 school years of education and most
were repeat donors (57.8%) (Table 1). First-time donors, donors
who rarely or never ate meat, those who reported taking
iron supplementation or aspirin, who had stomachache, black
tarry stools or hematochezia, and women who  reported fre-
quent and heavy menstrual ﬂows and had a higher number of
blood donations in the previous 13 months were more  likely to
be deferred. There was no association between deferral due to
low Hct and gender, race/ethnicity, education level, number
of blood donations, type of diet, frequency of consumption
of eggs and dairy products, use of multivitamins, duration
of menstrual ﬂow, number of pregnancies, cigarette smoking,
endoscopy, or intake of other pain relievers (Table 2). Donors
who reported taking aspirins [OR = 4.08; 95% conﬁdence inter-
val (95%CI): 2.45–7.06], taking iron supplementation (OR = 3.95;
95%CI: 1.58–11.27), stomachache (OR = 1.75; 95%CI: 1.26–2.44),
black tarry stools (OR = 2.73; 95%CI: 1.49–5.22) and hema-
tochezia (OR = 3.01; 95%CI: 1.48–6.52) were more  likely to be
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Table 2 – Type of diet, intake of meat,  eggs and dairy products, vitamin and iron supplementation, aspirin intake,
menstrual characteristics, number of pregnancies, cigarette smoking, gastrointestinal signals and symptoms,
endoscopy, use of pain relievers and number of donations among accepted and deferred donors.
Variable DA (n = 400) DD (n = 456) Total (n = 856) p-Value
n % n % n %
Type of diet
General 393 98.3 448 98.2 841 98.2 0.995
Ovo-lacto-vegetarian 6 1.5 7 1.5 13 1.5
Vegan 1 0.3 1 0.2 2 0.2
Intake of meat
Never or rarely 16 4.0 36 7.9 52 6.1 0.001
Once a week 15 3.8 39 8.6 54 6.3
Twice a week 54 13.5 79 17.3 133 15.5
3–5 times/week 133 33.3 132 28.9 265 31.0
Everyday 182 45.5 170 37.3 352 41.1
Intake of egg
Never or rarely 132 33.0 141 30.9 273 31.9 0.854
Once a week 106 26.5 133 29.2 239 27.9
Twice a week 85 21.3 99 21.7 184 21.5
3–5 times/week 58 14.5 59 12.9 117 13.7
Everyday 19 4.8 24 5.3 43 5.0
Intake of dairy products
Never or rarely 36 9.0 58 12.7 94 11.0 0.098
Once a week 8 2.0 16 3.5 24 2.8
Twice a week 18 4.5 16 3.5 34 4.0
3–5 times/week 27 6.8 42 9.2 69 8.1
Everyday 311 77.8 324 71.1 635 74.2
Vitamin supplements (over 12 months)
Yes 40 10.0 57 12.5 97 11.3 0.281
Missing 0 0.0 3 0.7 3 0.4
Vitamin supplements with iron over 12 months
Yes 25 71.4 35 68.6 60 69.8 0.969
Iron supplementation (12 months)
Yes 6 1.5 24 5.3 30 3.5 0.005
Aspirins (at least once a week)
Yes 24 6.0 88 19.3 112 13.1 <0.001
Frequency of menstruation (12 months)
Once a month 305 76.3 323 70.8 628 73.4 0.001
Twice a month 4 1.0 24 5.3 28 3.3
Each 40 days 5 1.3 13 2.9 18 2.1
Do not menstruate 54 13.5 47 10.3 101 11.8
Missing 32 8.0 49 10.7 81 9.5
Duration of menstruation
1–3 days 78 19.5 90 19.7 168 19.6 0.174
>3 and <7 days 231 57.8 256 56.1 487 56.9
>7 days 8 2.0 19 4.2 27 3.2
Do not menstruate 54 13.5 47 10.3 101 11.8
Missing 29 7.3 44 9.6 73 8.5
Menstruation ﬂow (12 months)
Light 43 10.8 59 12.9 102 11.9 0.031
Moderate 205 51.3 199 43.6 404 47.2
Heavy (clots) 69 17.3 106 23.2 175 20.4
Do not menstruate 54 13.5 47 10.3 101 11.8
Missing 29 7.3 45 9.9 74 8.6
Number of pregnancies
0 168 42.0 214 46.9 382 44.6 0.067
1 75 18.8 50 11.0 125 14.6
2 58 14.5 71 15.6 129 15.1
3 44 11.0 52 11.4 96 11.2
4 11 2.8 14 3.1 25 2.9
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Table 2 (Continued)
Variable DA (n = 400) DD (n = 456) Total (n = 856) p-Value
n % n % n %
5 10 2.5 6 1.3 16 1.9
≥6 8 2.0 8 1.8 16 1.9
Missing 26 6.5 41 9.0 67 7.8
Cigarette smoking
Non-smoker 328 82.0 400 87.7 728 85.0 0.061
Non-smoker >3 months 15 3.8 13 2.9 28 3.3
smoker 57 14.3 43 9.4 100 11.7
Number of cigarettes smoked/day
<5 15 27.8 15 33.3 30 30.3 0.142
≥5 and <10 15 27.8 13 28.9 28 28.3
≥10 and <15 9 16.7 8 17.8 17 17.2
≥15 and <21 11 20.4 2 4.4 13 13.1
≥21 and <31 1 1.9 1 2.2 2 2.0
≥30 and <41 0 0.0 1 2.2 1 1.0
Missing 3 5.6 5 11.1 8 8.1
Stomachache
Yes 106 26.5 187 41.0 293 34.2 <0.001
Endoscopy
Yes 81 20.3 112 24.6 193 22.6 0.301
Pain reliever use
Yes 36 9 64 14.0 100 11.7 1
Black tarry stools
Yes 19 4.8 70 15.4 89 10.4 <0.001
Hematochezia
Yes 13 3.3 41 9.0 54 6.3 0.001
Number of donations (lifetime)
0 69 17.3 98 21.5 167 19.5 0.56
1 34 8.5 52 11.4 86 10.0
2 30 7.5 47 10.3 77 9.0
3 31 7.8 30 6.6 61 7.1
4 29 7.3 33 7.2 62 7.2
>5 0 0.0 0 0.0 0 0.0
Missing 207 51.8 196 43.0 403 47.1
Number of donations (13 months)
0 147 36.8 197 43.2 344 40.2 0.007
1 73 18.3 92 20.2 165 19.3
2 113 28.3 96 21.1 209 24.4
3 60 15.0 38 8.3 98 11.4
4 4 1.0 6 1.3 10 1.2
5–7 0 0.0 1 0.2 1 0.1
Missing 3 0.8 26 5.7 29 3.4DA: donor accepted; DD: donor deferred.
deferred. Donors who  smoked were more  likely to be consid-
ered eligible (OR = 0.61; 95%CI: 0.37–0.98). For women, having
more  than one menstrual period per month was associated
with being deferred (OR = 4.14; 95%CI: 1.45–14.96).
Mean Hct (41.18 ± 2.46 vs. 35.83 ± 1.61; p-value <0.001),
Hb (13.6 ± 3.75 vs. 12.02 ± 1; p-value <0.001), serum iron
(79.77 ± 33.29 vs. 60.93 ± 34.13; p-value <0.001), transferrin
saturation (24.7 ± 10.5 vs. 18.2 ± 18.2; p-value <0.001), trans-
ferrin (340.6 ± 56.36 vs. 348.6 ± 58.71; p-value = 0.041) and
ferritin levels (50.56 ± 40.13 vs. 43.26 ± 51.54; p-value = 0.022)
were signiﬁcantly higher among eligible candidates com-
pared to deferred donors. Transferrin (340.6 + 56.36 vs.348.6 + 58.71; p-value = 0.041) was higher among deferred
donors.
ID was found in 504 (63.8%) women and 29 (43.9%) men.
Risk factors associated with ID among women were repeat
donations, younger age, higher frequency, longer duration and
higher intensity of menstruation, and higher number of dona-
tions in the previous 13 months. ID was less frequent among
smokers (Table 3). In the multivariate analyses, risk factors
associated with ID were repeat donation (OR = 2.31; 95%CI:
1.57–3.41) and being deferred at the Hct screening (OR = 2.37;
95%CI: 1.68–3.86). Otherwise, donors who reported smok-
ing (OR = 0.56; 95%CI: 0.34–0.92) and women in menopause,
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Table 3 – Type of donor, age, race/ethnicity, educational level, type of diet, intake of meat,  eggs and dairy products,
vitamin and iron supplementation, menstrual period characteristics, number of pregnancies, cigarette smoking,
gastrointestinal signals and symptoms, endoscopy, use of pain relievers and number of donations of prospective female
donors with and without iron depletion.
Variable Iron depletion p-Value
No (n = 286) Yes (n = 504) Total (n = 790)
n % n % n %
Type of donor
First-time 81 28.3 93 18.5 174 22.0 <0.001
Sporadic 32 11.2 43 8.5 75 9.5
Repeat 133 46.5 304 60.3 437 55.3
Missing 40 14.0 64 12.7 104 13.2
Age
18–24 78 27.3 110 21.8 188 23.8 0.001
25–34 99 34.6 153 30.4 252 31.9
35–44 48 16.8 153 30.4 201 25.4
45–54 43 15.0 62 12.3 105 13.3
55–65 16 5.6 20 4.0 36 4.6
Missing 2 0.7 6 1.2 8 1.0
Race/ethnicity
Asian 9 3.1 7 1.4 16 2.0 0.365
White 157 54.9 272 54.0 429 54.3
Indian 1 0.3 5 1.0 6 0.8
Black 39 13.6 69 13.7 108 13.7
Mixed 77 26.9 150 29.8 227 28.7
Missing 3 1.0 1 0.2 4 0.5
Educational level
1 to 8 years 33 11.5 80 15.9 113 14.3 0.227
8 to 11 years 133 46.5 216 42.9 349 44.2
>12 years 120 42.0 208 41.3 328 41.5
Type of diet
General 282 98.6 494 98.0 776 98.2 0.063
Ovo-lacto-vegetarian 2 0.7 10 2.0 12 1.5
Vegan 2 0.7 0 0.0 2 0.3
Intake of meat
Never or rarely 16 5.6 33 6.5 49 6.2 0.574
Once a week 14 4.9 36 7.1 50 6.3
Twice a week 45 15.7 78 15.5 123 15.6
3–5 times/week 84 29.4 157 31.2 241 30.5
Everyday 127 44.4 200 39.7 327 41.4
Intake of egg
Never or rarely 99 34.6 153 30.4 252 31.9 0.498
Once a week 72 25.2 147 29.2 219 27.7
Twice a week 57 19.9 112 22.2 169 21.4
3–5 times/week 40 14.0 68 13.5 108 13.7
Everyday 18 6.3 24 4.8 42 5.3
Intake of dairy products
Never or rarely 22 7.7 65 12.9 87 11.0 0.179
Once a week 7  2.4 8 1.6 15 1.9
Twice a week 13 4.5 17 3.4 30 3.8
3–5 times/week 25 8.7 38 7.5 63 8.0
Everyday 219 76.6 376 74.6 595 75.3
Vitamin supplements over 12 months
Yes 30 9.3 63 11.8 93 10.9 0.449
Vitamin supplements with iron over 12 months
Yes 17 70.8 40 69 57 69.5 1
Iron supplementation (over 12 months)
Yes 8 2.5 20 3.8 28 3.3 0.516
Aspirin (at least one a week)
Yes 37 11.5 70 13.1 107 12.5 0.793
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Table 3 (Continued)
Variable Iron depletion p-Value
No (n = 286) Yes (n = 504) Total (n = 790)
n % n % n %
Menstruation (last 12 months)
Once a month 212 74.1 415 82.3 627 79.4 0.007
Twice a month 8 2.8 20 4.0 28 3.5
Every 40 days 9 3.1 9 1.8 18 2.3
Do not menstruate 50 17.5 50 9.9 100 12.7
Missing 7 2.4 10 2.0 17 2.2
Duration of menstruation
1–3 days 71 24.8 96 19.0 167 21.1 <0.001
>3 and <7 days 156 54.5 331 65.7 487 61.6
>7 days 3 1.0 24 4.8 27 3.4
Do not menstruate 50 17.5 50 9.9 100 12.7
Missing 6 2.1 3  0.6 9  1.1
Menstruation ﬂow (last 12 months)
Light 45 15.7 56 11.1 101 12.8 <0.001
Moderate 145 50.7 259 51.4 404 51.1
Heavy (clots) 40 14.0 135 26.8 175 22.2
Do not menstruate 50 17.5 50 9.9 100 12.7
Missing 6 2.1 4 0.8 10 1.3
Number of pregnancies
0 138 48.3 242 48.0 380 48.1 0.888
1 45 15.7 80 15.9 125 15.8
2 50 17.5 79 15.7 129 16.3
3 35 12.2 61 12.1 96 12.2
4 6 2.1 19 3.8 25 3.2
5 5 1.7 11 2.2 16 2.0
>5 5 1.7 11 2.2 16 2.0
Missing 2 0.7 1 0.2 3 0.4
Cigarette smoking
non-smoker 235 82.2 444 88.1 679 85.9 0.05
non-smoker >3 months 8 2.8 13 2.6 21 2.7
smoker 43 15.0 47 9.3 90 11.4
Number of cigarettes smoked/day
<5 9 23.1 18 38.3 27 31.4 0.287
≥5 and <10 12 30.8 15 31.9 27 31.4
≥10 and <15 6 15.4 7 14.9 13 15.1
≥15 and <21 8 20.5 4 8.5 12 14.0
≥21 and <31 1 2.6 1 2.1 2 2.3
≥ 30 and <41 0 0.0 1 2.1 1 1.2
Missing 3 7.7 1 2.1 4 4.7
Stomachache
Yes 100 31.0 178 33.4 278 32.5 0.982
Endoscopy
Yes 64 19.8 116 21.8 180 21.0 0.74
Pain reliever use
Yes 30 9.3 63 11.8 93 10.9 0.706
Black tarry stools
Yes 24 7.4 55 10.3 79 9.2 0.315
Hematochezia
Yes 15 4.6 31 5.8 46 5.4 0.704
Number of donations (lifetime)
0 73 25.5 93 18.5 166 21.0 0.352
1 31 10.8 49 9.7 80 10.1
2 24 8.4 47 9.3 71 9.0
3 24 8.4 35 6.9 59 7.5
4 19 6.6 43 8.5 62 7.8
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Table 3 (Continued)
Variable Iron depletion p-Value
No (n = 286) Yes (n = 504) Total (n = 790)
n % n % n %
5–7 0 0.0 0 0.0 0 0.0
Missing 115 40.2 237 47.0 352 44.6
Number of donations (13 months)
0 144 50.3 183 36.3 327 41.4 0.008
1 51 17.8 101 20.0 152 19.2
2 58 20.3 137 27.2 195 24.7
3 24 8.4 60  11.9 84 10.6
4 3 1.0 3 0.6 6 0.8
5 0 0.0 1 0.2 1 0.1
Missing 6 2.1 19 
Table 4 – Independent risk factors for deferral due to low
hematocrit in 856 male and female and for iron
depletion in 790 prospective female blood donors.




Aspirin intake 4.08 2.45–7.06
Iron supplementation 3.95 1.58–11.27
Stomachache 1.75 1.26–2.44
Black tarry stools 2.73 1.49–5.22
Hematochezia 3.01 1.48–6.52
Smoking 0.61 0.37–0.98
>One menstruation/month 4.14 1.45–14.96
Iron depletion
Repeat donation 2.31 1.57–3.41




















Do not menstruate 0.44 0.27–0.71
r after hysterectomy, or who did not menstruate anymore
OR = 0.44; 95%CI: 0.27–0.71) were less likely to present ID
Table 4).
iscussion
his case–control study found unusual risk factors related
o donor deferral due to low Hct. Donors who reported tak-
ng aspirins and iron supplementation at least once a week
ver the previous 12 months were four times more  likely to
e deferred. Additionally, GI symptoms such as stomachache,
lack tarry stools and hematochezia were associated with
 higher rate of deferral. A well-known risk factor of defer-
al due to low Hct, more  than one menstruation per month,
as also detected. Smokers were less likely to be deferred
han non-smokers. Among women, repeat donation and being
eferred in the Hct screening test were highly associated with
D. Women who reported smoking and did not menstruate
ere less likely to present ID.
Women were more  likely to be deferred due to low Hct
han men. Normal iron stores in men  and women are 1000 mg
nd 350 mg,  respectively. Iron stores in women are usually3.8 25 3.2
lower due to menstruation and pregnancy. A single whole
blood donation removes 200–250 mg  of iron from the donor,
an amount sufﬁcient to totally deplete the average women’s
stores.14 The last consequence of ID is anemia. In this blood
center, the most common causes of deferral among ﬁrst-time
donors were high-risk behavior, followed by low Hct. Women
are more  likely than men  to be deferred for low Hct in their
ﬁrst donation compared to when they try to become a repeat
donor.15 Moreover, in a longitudinal study conducted over
11 years in the same blood center, 18,104 (13.6%) of 133,056
females were deferred for low Hct at some time after their
ﬁrst donation.16 The ﬁndings in this study indicate that more
than one menstruation in a month together with the inten-
sity and duration of menstruation may be useful to predict
the likelihood of deferral among women. Moreover, the asso-
ciation found between ID and repeat donation among women
can explain the higher deferral rate reported in the aforemen-
tioned longitudinal study.
A signiﬁcant ﬁnding was the association between the rate
of deferral for low Hct and GI signs and symptoms such as
stomachache, black tarry stools and hematochezia. Aspirin
intake was also associated with a higher chance of deferral
due to low Hct; a frequent adverse event of aspirin intake is GI
bleeding. GI bleeding is a common problem found in the gen-
eral clinic and emergency room but not among blood donors.
Annen et al.7 reported GI bleeding in four (5.4%) of 74 donors,
previously deferred for low HB levels, who were determined to
be anemic by their physicians. Dark tarry stools can indicate
an upper GI bleed, and hematochezia can indicate a lower GI
bleed. Both conditions have an annual incidence that ranges
from 60 to 177 episodes per 100,000 persons in the US, and a
mortality rate varying between 10%-20%.17 Although GI bleed-
ing can be a consequence of a benign disease, it can indicate
potential life-threating hemorrhages or malignant neoplasms
and further investigation is required. Anemia can indicate an
illness, and should not be ignored. The primary function of
blood banks is not to diagnose diseases in donors. Neverthe-
less, questions that identify GI bleeding in deferred donors due
to low Hct may help to prompt donors to seek diagnosis and
treatment of GI pathologies.
A controversial ﬁnding was the association between smok-
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the association between nutritional and non-nutritional vari-
ables in adult women, reported that smoking was associated
with ID, and the use of alcohol was associated with increased
iron. Milman et al.19 evaluated the relationship between risk
factors for cardiovascular disease and ferritin in non-blood
donors. Among women, the authors found no association
between smoking and serum ferritin. Similarly, Cable et al.20
found elevated ferritin levels in smoking donors. We speculate
that smoking may be a confounding factor of other behav-
iors known to elevate ferritin, such as a sedentary lifestyle
and/or regular alcohol drinking. Further studies to evaluate
the relationship of smoking among donors, lifestyle and lev-
els of ferritin can add knowledge to better understand this
issue.
There were some limitations in the current study. First,
as the study used a case–control design, it was not possi-
ble to estimate the prevalence and relevance of the studied
risk factors in this blood donor population. The advantage of
the study design was to sensitize the identiﬁcation of some
uncommon risk factors. Second, recall bias is also common
in case-control studies. Donors who were deferred were more
likely to remember and report risk factors for anemia. Third,
to deﬁne ID based only on ferritin values can be imprecise. In
the medical literature, many  deﬁnitions for ID and iron deﬁ-
ciency mainly depend on the level of ferritin, the researched
population and the gender. A deﬁnition was chosen for this
study based on a previous study that compared levels of fer-
ritin and marrow iron, a sensitive marker of ID.11 Additionally,
to avoid misclassiﬁcation of ID donors with inﬂammatory
conditions and normal or elevated ferritin as non-ID, trans-
ferrin saturation less than 20% as an ID marker was also
considered.
To manage blood donors deferred for low Hct/Hb and ID
is a challenge. Routine administration of iron replacement
therapy has the advantage of not overburdening health ser-
vices, preventing signs and symptoms of iron deﬁciency and
increasing donor retention.21 However, this practice has the
possible disadvantage of masking a chronic GI bleeding or an
underlying malignancy. Another feasible strategy is to screen
ﬁrst-time donors for ferritin. Those with lower ferritin lev-
els would be encouraged to donate blood less frequently.
Blood banks must consider that ferritin is an expensive test,
and results are not readily available to make an immediate
decision.22 Finally, to increase donation intervals has a limited
impact on donor iron status23 and keeps donors away from
the blood banks. The risk factors related to donor deferral
for low Hct and ID found in this study can help blood banks
design algorithms and improve donor notiﬁcation and refer-
ral. The experience gained on notiﬁcation and counseling of
blood donors with positive test results could serve as a guide
to notify and refer donors deferred for low Hct. Blood banks
can improve their relationship with blood donors and increase
the recognition of their service in the community for the public
service they are providing.Conﬂicts  of  interest
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